- Home
- ATER vs KZIA Comparison
ATER vs KZIA Comparison
Compare ATER & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- KZIA
- Stock Information
- Founded
- ATER 2014
- KZIA 1994
- Country
- ATER United States
- KZIA Australia
- Employees
- ATER N/A
- KZIA N/A
- Industry
- ATER Home Furnishings
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- KZIA Health Care
- Exchange
- ATER Nasdaq
- KZIA Nasdaq
- Market Cap
- ATER 10.4M
- KZIA 9.0M
- IPO Year
- ATER N/A
- KZIA 1999
- Fundamental
- Price
- ATER $0.98
- KZIA $7.95
- Analyst Decision
- ATER
- KZIA Strong Buy
- Analyst Count
- ATER 0
- KZIA 2
- Target Price
- ATER N/A
- KZIA $14.00
- AVG Volume (30 Days)
- ATER 121.7K
- KZIA 19.0K
- Earning Date
- ATER 08-13-2025
- KZIA 06-05-2025
- Dividend Yield
- ATER N/A
- KZIA N/A
- EPS Growth
- ATER N/A
- KZIA N/A
- EPS
- ATER N/A
- KZIA N/A
- Revenue
- ATER $85,668,000.00
- KZIA $1,549,158.00
- Revenue This Year
- ATER N/A
- KZIA N/A
- Revenue Next Year
- ATER $7.48
- KZIA $49.25
- P/E Ratio
- ATER N/A
- KZIA N/A
- Revenue Growth
- ATER N/A
- KZIA 248983.08
- 52 Week Low
- ATER $0.90
- KZIA $2.86
- 52 Week High
- ATER $3.84
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- ATER 36.18
- KZIA 49.06
- Support Level
- ATER $0.94
- KZIA $7.69
- Resistance Level
- ATER $1.07
- KZIA $8.39
- Average True Range (ATR)
- ATER 0.05
- KZIA 0.65
- MACD
- ATER 0.01
- KZIA 0.05
- Stochastic Oscillator
- ATER 33.41
- KZIA 64.55
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.